Skip to content

Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation

Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02995577
Enrollment
30
Registered
2016-12-16
Start date
2016-12-31
Completion date
Unknown
Last updated
2016-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Single Ventricle Physiology

Brief summary

The purpose of this study is to investigates serum and stool biomarkers as predictors for post-operative feeding intolerance in infant patients with complex congenital heart defects who undergo single ventricle staged palliation surgery.

Interventions

OTHERFeeding tolerant
OTHERFeeding intolerant
OTHERNecrotizing enterocolitis

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to 3 Years
Healthy volunteers
No

Inclusion criteria

* Full term gestational period (37 weeks gestation or greater) * minimum of 2.5kg or greater body weight * diagnosis of single ventricle physiology, or complex congenital cyanotic heart disease requiring staged palliation surgery in the form of Norwood-type procedure, systemic-to-pulmonary artery shunt, or pulmonary artery banding.

Exclusion criteria

* Have diseases affecting other organs, * have major congenital anomalies such as Hirschsprung disease, imperforate anus, CHARGE syndrome, or VACTERL association.

Design outcomes

Primary

MeasureTime frameDescription
Level of most abundant serum protein as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgeryWe will select two proteins with top changes that are involved in the pathways for intestinal inflammation, and levels will be determined with either ELISA or other techniques that are available.
Level of second most abundant serum protein as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
Level of stool biomarker interleukin-8 (IL-8) as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery
Level of stool biomarker calprotectin as determined by ELISAbaseline (3-5 days after initial cardiac surgery), within three weeks of the initial cardiac surgery

Countries

United States

Contacts

Primary ContactSupriya Nair, MD
Supriya.Nair@uth.tmc.edu832-582-0683
Backup ContactJ. Marc Rhoads, MD
J.Marc.Rhoads@uth.tmc.edu(713) 500-5663

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026